TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04510727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Description: VivoSight Dx OCT system from Michelson Diagnostics Ltd. OCT will be used to visualize the tumor and lesion in the skin.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curettage & Desiccation (C&D) Procedure
Description: Standard of care C\&D where the basal cell carcinoma lesion will be scraped to its base using a Fox dermal curette and an electrodesiccation machine.
Study: NCT06066489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational program about VAP
Description: An educational program about VAP that includes VAP bundle from CDC as core measures , equipment related measures and general measures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational program about VAP
Description: An educational program about VAP that includes VAP bundle from CDC as core measures , equipment related measures and general measures.
Study: NCT04861207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: The conditioning regimen used will be cladribine-based at a dose of 5 mg / m2 for 5 days (iv.) and total body irradiation at a total dose of 12 Gy in three fractions.
Study: NCT06354621

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin-D supplementation
Description: Participants receiving a daily dose of vitamin D supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin-D supplementation
Description: Participants receiving a daily dose of vitamin D supplementation
Study: NCT06509100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Altitudes USA
Description: Experimental participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes educational and therapeutic content that is tailored to each individual and their current needs and experiences, including psychoeducation, supporting their loved one, self- care, social support, and so on. Further, the platform includes a moderated social media function, where users and family peer workers can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
Study: NCT04745832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zandelisib
Description: Zandelisib 60 mg capsules taken daily for two cycles followed by intermittent schedule starting at Cycle 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV 375 mg/m2 for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV 375 mg/m2 for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine IV 90 mg/m2 on Days 1 and 2 for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: Cyclophosphamide, Vindcristine IV, and Prednisone daily orally
Study: NCT06133010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile liquid for injection
Study: NCT05497063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-COSPE® tablets
Description: One tablet of G-COSPE® tablets, 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Study: NCT05936645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A temporary sub-placental Uterine Tourniquet in management of Placenta Accreta Spectrum disorder by a retrograde cesarean hysterectomy (Bladder Last)
Description: Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde cesarean hysterectomy (Bladder Last) for management of Placenta Accreta Spectrum disorder
Description: Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy.
Study: NCT05780463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0420
Description: MP0420 is a multi-valent DARPin® molecule (designed ankyrin repeat protein), consisting of 5 DARPin® domains.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% sodium chloride solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Antiviral agent
Study: NCT05780840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dihydroxyacetone
Description: Application of 10% dihydroxyacetone (2 mg per square cm skin)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dihydroxyacetone
Description: Application of 10% dihydroxyacetone (2 mg per square cm skin)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Application of lotion to the skin (2 mg per square cm skin)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of lotion to the skin (2 mg per square cm skin)
Study: NCT05107414

Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: Participants have previously undergone a total knee replacement surgery.

Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: Participants have previously undergone a total knee replacement surgery.

Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: Participants have previously undergone a total knee replacement surgery.
Study: NCT05780463

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Antiviral agent
Study: NCT04154540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion analysis
Description: Gait and posture recording

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion analysis
Description: Gait and posture recording
Study: NCT05567003

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous transhepatic cholangioscopic (PTCS) laser incision
Description: Infrared percutaneous transhepatic cholangioscopic guided holmium laser incision for treatment of benign biliary strictures.
Study: NCT00012818

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: relaxation technique

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: educational program
Study: NCT04794816

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT04486066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: In MBSR, participants meet by video for 2 hours per week for 8 weeks in a group format and receive instruction in mindfulness meditation according to a standardized curriculum, are given daily homework, participate in group discussions, and can ask questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Chronic Pain
Description: Cognitive Behavioral Therapy (CBT) is the most widely used non-pharmacologic intervention for chronic pain and a version of CBT specifically addressing chronic pain (CBT-CP) has been developed for use in VA with Veterans. Fundamentally, CBT is an approach that seeks to ameliorate dysfunctional relationships between an individual's thoughts, feelings, and behaviors to improve functioning and quality of life. At our site, the CBT-CP format has been adapted for clinical use (i.e., as part of usual clinical care) to 8 video sessions in a group format, while retaining all essential elements.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Veterans randomized to usual care will continue to be followed by their usual care providers for all medical and mental health care. This can include continued use of medications, specialty referrals and other usual elements of care. They will be asked to not enroll in the specific MBSR or CBT-CP interventions during the 8-month study period, but can attend other groups interventions, such as CBT-Insomnia, Acceptance and Commitment Therapy for Chronic Pain, and other groups for chronic pain and PTSD as directed by their treating providers. They can also enroll in MBSR or CBT-CP at the completion of the study.
Study: NCT05657587

Intervention type: DEVICE
Intervention: SPRINT PNS
Description: Each subject will have 2 leads placed for 60 days. The Sprint system delivers mild electrical stimulation to the shoulder. The Sprint system includes up to two leads (small wires) that are placed through your skin in your shoulder. The leads attach to devices worn on your body that delivers stimulation (stimulators).
Study: NCT05512650

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Meditation
Description: Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Meditation
Description: Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-VR Meditation
Description: Participants will engage and follow along with a 10-20 minute guided meditation on a computer screen placed before them. The meditation program may include simulated movement visuals, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-VR Meditation
Description: Participants will engage and follow along with a 10-20 minute guided meditation on a computer screen placed before them. The meditation program may include simulated movement visuals, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
Study: NCT06559202

Intervention type: DIAGNOSTIC_TEST
Intervention: chest and abdominoplevic CT
Description: chest and abdominopelvic computed tomography on the same day for health screening purposes
Study: NCT06491797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate reactivation
Description: Our intervention will be booster measure of the existing PTP elements that will be designed for each unit that has been randomized to the immediate intervention group. The booster will consist in a reactivation through audit and feedback of 2-3 elements of the PTP program. The selection of the elements to boost will be done locally in each unit through a coordinated discussion between representants of the PTP organization and representants of the unit's medical and nursing professionals. This will create an adaptable intervention that will feature selected standards among the list of 36 existing standards. The boost will be performed over 3 months
Study: NCT04925791

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: standardized pre-conditioning treatment
Description: 3 rounds of 5 minutes of full occlusion alternating with 5 minutes of reperfusion while seated.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Partial occlusion
Description: 3 rounds of 5 minutes of partial occlusion alternating with 5 minutes of reperfusion while seated.
Study: NCT05739864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: This intervention is represented by the administration, in the recipients' gut, of super - donor microbiota through FMT

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo FMT
Description: This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
Study: NCT06203444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: The study drug will be administered in dose of 50 mg bid
Study: NCT06173362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Given abiraterone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Given darolutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given prednisone
Study: NCT04898205

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treadmill Exercise
Description: The cardiopulmonary rehabilitation protocol utilizes progressive treadmill exercise with alternating increases in intensity and incline with no more than 0.5 Met increase per session.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Treadmill Exercise
Description: The cardiopulmonary rehabilitation protocol utilizes progressive treadmill exercise with alternating increases in intensity and incline with no more than 0.5 Met increase per session.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Treadmill Exercise
Description: The cardiopulmonary rehabilitation protocol utilizes progressive treadmill exercise with alternating increases in intensity and incline with no more than 0.5 Met increase per session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Exercise
Description: The cardiopulmonary rehabilitation protocol utilizes progressive treadmill exercise with alternating increases in intensity and incline with no more than 0.5 Met increase per session.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Concentrated Oxygen
Description: Supplemental oxygen from a concentrator (6 liters per minute) will be provided via nasal cannula regardless of oxygen saturation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Concentrated Oxygen
Description: Supplemental oxygen from a concentrator (6 liters per minute) will be provided via nasal cannula regardless of oxygen saturation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Concentrated Oxygen
Description: Supplemental oxygen from a concentrator (6 liters per minute) will be provided via nasal cannula regardless of oxygen saturation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentrated Oxygen
Description: Supplemental oxygen from a concentrator (6 liters per minute) will be provided via nasal cannula regardless of oxygen saturation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Concentrated Air
Description: Room air will be delivered through an concentrator provided via nasal cannula.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Concentrated Air
Description: Room air will be delivered through an concentrator provided via nasal cannula.
Study: NCT06324227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimodal music therapy
Description: music therapy
Study: NCT06152601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anticipated bipedal standing position in the immediate post-operative phase
Description: Realization of a first stand-up within 6 hours after entry into PACU or extubation for admitted patients intubated, in PACU or on admission to ICU by a state-certified physiotherapist.~Immediately postoperatively, during his stay in a Intensive Care Unit, the patient will be offered a physiotherapy session including a lifting phase in a bipedal standing position.
Study: NCT03575000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Description: This is an open-label study, so there is no comparator group. As such there is only one arm. Subjects will receive bromocriptine at a starting dose of 2.5mg daily which will be increased, if tolerated, to 5mg daily after one week. Bromocriptine will be continued for a total of 6 weeks. Laboratory investigations, telephonic interviews, and face to face visits with subjects will be conducted before, during, and after the time period that bromocriptine will be used as detailed in the study design section.
Study: NCT06334315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel / Ethinyl Estradiol Pill
Description: Standard pill packs containing 21 active pills and 7 placebo pills
Study: NCT05858151

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food system and demand generation
Description: The Global Alliance for Improved Nutrition (GAIN) will implement the Transforming Food Systems to Improve Diet Quality and Resilience for the Most Vulnerable program, which will use a market-based approach to improving diets through food systems. The set of interventions proposed is based on characteristics and challenges of the food environments of bottom of pyramid consumers in Mozambique. GAIN will focus on elements of the food environment related to accessibility, affordability, and desirability of animal source foods (ASFs) in Mozambique.
Study: NCT06322862

Intervention type: OTHER
Group type: OTHER
Intervention: Indocyanine green
Description: Intraoperative perfusion assessment with ICG Fluorescence Angiography (ICG-FA) in standard approved doses
Study: NCT05718518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC11 tablets
Description: Part 1: Subjects will receive ASC11 tablets on single ascending doses with proposed dose levels of ASC11 tablets: 100mg (cohort 1), 200 mg (cohort 2), 400mg (cohort 3) and 800 mg (cohort 4).~Part 2: Subjects will receive ASC11tablets 100 to 300 mg (including 3 cohorts) and ASC11 tablets 300 mg(cohort 4) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive ASC11 tablets two single 200 mg or 300 mg doses (fed or fasted)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1 and 2: Subjects will be randomized to receive placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV tablets
Description: Part 1: Subjects will receive RTV tablets on 100 mg (cohort 1-4). Part 2: Subjects will receive RTV tablets 100 mg (including 3 cohorts) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive two single 100 mg doses (fed or fasted)
Study: NCT05899816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection
Study: NCT04463979

Intervention type: OTHER
Intervention: Impact of Cerebellar Functional Topography on Cognition and Motor Ataxia
Description: Participants in this study will undergo surgical resection of their cerebellar or brain tumor (as per standard of care), as well as clinical and radiographic assessment, including: neurological physical examination (including Karnofsky Performance Scale (KPS) if conducted per Standard of Care), and magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography, prior to, immediately after, at one-month, 6-month, and 1-year follow-up status post-surgical resection. These data will also be collected at 18-month (±60 days) and 24-month (±60 days) visits post-surgery, if regular office visits with the neurosurgeon are scheduled at these two time points.~Only at baseline, the following will be conducted: Brief Ataxia Rating Scale (BARS) assessment score, Cerebellar Cognitive Affective Scale (CCAS/Schmahmann syndrome) scale score, Montreal Cognitive Assessment (MoCA) assessment, and a quality of life (QoL) assessment using the SF-36 questionnaire.
Study: NCT06562998

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxifylline 400mg twice daily plus paclitaxel based regimens for 12weeks.
Study: NCT06324227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention
Description: no intervention
Study: NCT04946344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet & Exercise
Description: Participants will attend exercise and diet classes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants will attend healthy living classes and receive phone calls/emails/texts.
Study: NCT05539963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STIMULAN VG
Description: Participants will receive STIMULAN VG via implantation during debridement surgery on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Antibiotics
Description: Participants will receive Antibiotics per site-specific requirements.
Study: NCT06562998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxifylline 400mg twice daily plus paclitaxel based regimens for 12weeks.
Study: NCT05031260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: applying COMORAL®
Description: The individuals in the experimental group will be asked to come to the clinic to use COMORAL® three times a day, every day except Saturday and Sunday.